Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: The influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment

Physiological Research

Volumn 60, Issue 4, 2011, Pages 627-636

  Mraz M ^a   Lacinova Z ^a   Kavalkova P ^a   Haluzikova D ^a   Trachta, P ^a   Drapalova J ^a   Hanusova V ^a   Haluzik M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Fenofibrate; FGF 19; Obesity; Type 2 diabetes mellitus; Very low calorie diet

Indexed keywords

EID: 80053640115     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932099     Document Type: Article

References (32)

1. ANDERLOVA K, DOLEZALOVA R, HOUSOVA J, BOSANSKA L, HALUZIKOVA D, KREMEN J, SKRHA J, HALUZIK M: Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 56: 579-586,2007.
2. ANDERLOVA K, KREMEN J, DOLEZALOVA R, HOUSOVA J, HALUZIKOVA D, KUNESOVA M, HALUZIK M: The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. Physiol Res 55: 277-283, 2006.
3. BEIL U, CROUSE JR, EINARSSON K, GRUNDY SM: Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-Iipoprotein triglycerides. Metabolism 31: 438-444, 1982.
4. BRUFAU G, STELLAARD F, PRADO K, BLOKS VW, JONKERS E, BOVERHOF R, KUIPERS F, MURPHY EJ: Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52: 1455-1464, 2010.
5. CARIOU B, VAN HARMELEN K, DURAN-SANDOVAL D, VAN DIJK TH, GREFHORST A, ABDELKARIM M, CARON S, TORPIER GR, FRUCHART J-C, GONZALEZ FJ, KUIPERS F, STAELS B: The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281: 11039-11049,2006.
6. DOSTALOVA I, KAVALKOVA P, HALUZIKOVA D, LACINOVA Z, MRAZ M, PAPEZOVA H, HALUZIK M: Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93: 3627-3632, 2008a.
7. FU L, JOHN LM, ADAMS SH, YU XX, TOMLINSON E, RENZ M, WILLIAMS PM, SORIANO R, CORPUZ R, MOFFAT B, VANDLEN R, SIMMONS L, FOSTER J, STEPHAN J-P, TSAI SP, STEWART TA: Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603, 2004.
8. HALUZIK MM, ANDERLOVA K, DOLEZALOVA R, ADAMIKOVA A, HALUZIKOVA D, HOUSOVA J, SVACINA S, HALUZIK M: Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 58: 93-99, 2009.
9. HOLT JA, LUO G, BILLIN AN, BISI J, MCNEILL YY, KOZARSKY KF, DONAHEE M, WANG DY, MANSFIELD TA, KLIEWER SA, GOODWIN B, JONES SA: Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581-1591, 2003.
10. CHOI M, MOSCHETTA A, BOOKOUT AL, PENG L, UMETANI; M, HOLMSTROM SR, SUINO-POWELL K, XU HE, RICHARDSON JA, GERARD RD, MANGELSDORF DJ, KLIEWER SA: Identification of a hormonal basis for gallbladder filling. Nat Med 12: 1253-1255, 2006.
11. INAGAKI T, CHOI M, MOSCHETTA A, PENG L, CUMMINS CL, MCDONALD JG, LUO G, JONES SA, GOODWIN B, RICHARDSON JA, GERARD RD, REPA JJ, MANGELSDORF DJ, KLIEWER SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225, 2005.
12. INSULL W JR: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med 799:257-273, 2006.
13. ITOH N, ORNITZ DM: Evolution of the Fgf and Fgfr gene families. Trends Genet 20: 563-569, 2004.
14. LEFEBVRE P, CARIOU B, LIEN F, KUIPERS F, STAELS B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89: 147-191, 2009.
15. LUNDASEN T, GALMAN C, ANGELIN B, RUDLING M: Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260: 530-536, 2006.
16. MA K, SAHA PK, CHAN L, MOORE DD: Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116: 1102-1109, 2006.
17. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
18. NISHIMURA T, UTSUNOMIYA Y, HOSHIKAWA M, OHUCHI H, ITOH N: Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1444: 148-151, 1999.
19. PINEDA TORRA I, CLAUDEL T, DUVAL C, KOSYKH V, FRUCHART J-C, STAELS B: Bile acids induce the expression of the human peroxisome proliferator-activated receptor {alpha} gene via activation of the farnesoid X receptor. Mol Endocrinol 17: 259-272, 2003.
20. REICHE M, BACHMANN A, LÖSSNER U, BLÜHER M, STUMVOLL M, FASSHAUER M: Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42: 178-181, 2010.
21. RONTI T, LUPATTELLI G, MANNARINO E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64: 355-365, 2006.
22. SHEPHERD J, PACKARD CJ, BICKER S, LAWRIE TDV, MORGAN HG: Cholestyramine promotes receptor-mediated Iow-density-lipoprotein catabolism. N Engl J Med 302: 1219-1222, 1980.
23. SHIN DJ, OSBORNE TF: FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 284: 11110-11120, 2009.
24. SCHAAP FG, VAN DER GAAG NA, GOUMA DJ, JANSEN PL: High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228-1235, 2009.
25. SCHREUDER TC, MARSMAN HA, LENICEK M, VAN WERVEN JR, NEDERVEEN AJ, JANSEN PL, SCHAAP FG: The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G440-G445, 2010.
26. SMELT AHM: Triglycerides and gallstone formation. Clin Chim Acta 411: 1625-1631, 2010.
27. STUMVOLL M, JACOB S, WAHL HG, HAUER B, LOBLEIN K, GRAUER P, BECKER R, NIELSEN M, RENN W, HARING H: Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. J Clin Endocrinol Metab 85: 3740-3745, 2000.
28. TOMLINSON E, FU L, JOHN L, HULTGREN B, HUANG X, RENZ M, STEPHAN JP, TSAI SP, POWELL-BRAXTON L, FRENCH D, STEWART TA: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747, 2002.
29. XIE MH, HOLCOMB I, DEUEL B, DOWD P, HUANG A, VAGTS A, FOSTER J, LIANG J, BRUSH J, GU Q, HILLAN K, GODDARD A, GURNEY AL: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11: 729-735, 1999.
30. YU C, WANG F, JIN C, HUANG X, McKEEHAN WL: Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 280: 17707-17714, 2005.
31. YU C, WANG F, KAN M, JIN C, JONES RB, WEINSTEIN M, DENG C-X, McKEEHAN WL: Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275: 15482-15489, 2000.
32. ZHANG Y, LEE FY, BARRERA G, LEE H, VALES C, GONZALEZ FJ, WILLSON TM, EDWARDS PA: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103: 1006-1011, 2006.